Evidence map›Paper›PMID 41146799›Full record

ReviewCureus2025

Optimal Timing of Oral Anticoagulant Therapy Initiation Post-acute Ischemic Stroke: A Narrative Review.

Nicholas Aderinto, Lama H Aljamea, Faisal H Aljamea

Abstract readReview
In one paragraph

Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Nicholas AderintoMedicine, Ladoke Akintola University of Technology, Ogbomoso, NGA.
Lama H AljameaCollege of Medicine, King Faisal University, Al-Ahsa, SAU.
Faisal H AljameaMedicine and Surgery, Vision College, Riyadh, Riyadh, SAU.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Initiation of oral anticoagulation therapy after acute ischemic stroke requires the best trade-off between prevention of early recurrent embolic events and hemorrhagic transformation avoidance. While guidelines typically recommend starting therapy between 4 and 14 days, current evidence suggests that timing should be tailored to stroke severity, imaging findings, and individualized patient characteristics. This narrative review summarizes evidence from guidelines and clinical trials/observational studies published between 2013 and 2025, identified through PubMed, Web of Science, and Google Scholar. Summary of recent trials, including ELAN and TIMING, demonstrates that early initiation, i.e., within 48 hours to five days after minor or moderate strokes, is generally safe and associated with improved functional outcome and reduced mortality, without the risk of increased bleeding. Delayed initiation, however, is typically associated with augmented embolic events and does not provide an additional safety benefit. In general, the literature supports a patient-centered approach where early treatment is desirable for most cases, but larger infarcts, hemorrhage signs, or previous surgical procedures might call for a more cautious delay to establish stability.

Indexed as

acute ischaemic strokeatrial fibrillationdirect oral anticoagulants (doacs)oral anticoagulantstherapy initiation

Identifiers

PMID41146799
PMCPMC12554252

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.